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Edited by Varda RotterAbstract p205 is a member of the interferon-inducible p200
family of proteins that regulate cell proliferation. Over-expres-
sion of p205 inhibits cell growth, although its mechanism of ac-
tion is currently unknown. Therefore, we evaluated the eﬀect of
p205 on the p53 and Rb-dependent pathways of cell cycle regu-
lation. p205 expression results in elevated levels of p21, and acti-
vates the p21 promoter in vitro in a p53-dependent manner. In
addition, p205 induces increased expression of Rb, and binds di-
rectly to Rb and p53. Interestingly, p205 also induces growth
inhibition independent of p53 and Rb by delaying G2/M progres-
sion in proliferating cells, and is a substrate for Cdk2 kinase
activity. Finally, we have identiﬁed other binding partners of
p205 by a yeast two-hybrid screen, including the paired homeo-
domain protein HoxB2. Taken together, our results indicate that
p205 induces growth arrest by interaction with multiple tran-
scription factors that regulate the cell cycle, including but not en-
tirely dependent on the Rb- and p53-mediated pathways of
growth inhibition.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The interferon-inducible p200 (IFI-200) proteins are a highly
homologous family of proteins that are expressed in mouse
and man. They are characterized by the presence of one orAbbreviations: IFI-200, interferon-inducible p200 family; Cdk, cyclin-
dependent kinase; CAK, Cdk-activating kinase; PCNA, proliferating
cell nuclear antigen; GST, glutathione-S-transferase; 53BP, p53-bind-
ing protein; Miz1, c-Myc-interacting zinc-ﬁnger protein 1; AIM2,
absent in melanoma 2; MNDA, myeloid nuclear diﬀerentiation anti-
gen; DAPIN, domain in apoptosis and interferon response; PCR,
polymerase chain reaction; DMEM, Dulbecco’s modiﬁed Eagle’s me-
dium; PBS, phosphate buﬀered saline; BSA, bovine serum albumin;
SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electropho-
resis; MPRO, myeloid progenitor cell line
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doi:10.1016/j.febslet.2006.01.032two highly conserved C-terminal 200 amino acid domains,
which exists in two forms, a and b. The murine IFI-200 pro-
teins include p202a, p202b, p203, p204 and p205; and the hu-
man homologues are IFI-16, myeloid nuclear diﬀerentiation
antigen (MNDA), absent in melanoma 2 (AIM2), and IFIX
[1–5]. IFI-16, p202, and p204 have two 200 amino acid do-
mains, while MNDA, AIM2, IFIX, p203 and p205 have only
one domain. The 200 amino acid domains contain several
highly conserved features: an MFHATVAT region, thought
to be important for protein–protein interaction, an Rb-binding
site, a putative ATM-phosphorylation site, and a putative cy-
clin-dependent kinase 2 (Cdk2) phosphorylation site. In addi-
tion, all of the p200 family members, with the exception of
p202, have an N-terminal domain in apoptosis and interferon
response (DAPIN)/Pyrin domain. This domain is associated
with apoptosis and interferon response, and has been sug-
gested to be important for p200 protein dimerization. The
functions of the p200 family members appear to be distinct
from one another in that certain family members, IFI-16,
p202, p204, have been clearly shown to have anti-proliferative
eﬀects, while others have not: p203, MNDA [6–8]. In addition,
AIM2, was described as a potential tumor suppressor gene
in melanoma, is able to inhibit murine ﬁbroblast growth,
and enhance susceptibility to apoptosis under reduced serum
conditions [9].
We observed that p205 expression is induced by interleukin-
3 in hematopoietic progenitors during myeloid cell development
[10]. When over-expressed, p205 can inhibit the proliferation
of hematopoietic cell lines and primary bone marrow cells,
suggesting that p205 may function to promote growth arrest
and diﬀerentiation during hematopoietic development [11].
This function was dependent upon the presence of the DAPIN
domain, as well as the Rb-binding region in the C-terminus,
suggesting that p205 may regulate cell growth via Rb. Other
p200 family members also interact with Rb, p53BP1 and
E2F supporting a model in which p200 proteins may regulate
cell growth through Rb- and p53-speciﬁc pathways [16–21].
For example, p202 binds Rb and E2F proteins to promote
transcriptional repression E2F-responsive genes [16,17]. In
addition, p202 appears to bind and sequester p53BP, causing
in a decrease in p53 transcriptional activity, speciﬁcallyblished by Elsevier B.V. All rights reserved.
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However, a separate report indicates p202 actually increases
p21 expression [21]. These data illustrate that while p53 and
Rb seem to be involved in p202 action, although the precise
mechanism remains somewhat unclear. Furthermore, p202
and p204 have been shown to have opposite eﬀects in certain
cell models. Speciﬁcally, in a myoblast diﬀerentiation model,
p202 bound to and inhibited the activity of diﬀerentiation spe-
ciﬁc transcription factors, while forced expression of p204 pro-
moted diﬀerentiation [12,13]. To date, of the murine family
members, only p202 and p204 have been studied in regard to
their eﬀects on the cell cycle proteins. While we have previously
reported that p205 has growth inhibitory eﬀects in hematopoi-
etic cells and cell lines [11], the actual mechanism(s) by which
p205 exerts its growth inhibitory function with a single 200
amino acid domain remains to be determined. Therefore, to
investigate the mechanism(s) by which p205 inhibits cell prolif-
eration and determine if it was dependent on p53 and/or Rb,
we developed an inducible p205 expression system and tested
the eﬀect of conditional expression of p205 in p53 and Rb deﬁ-
cient cell lines. Further, we evaluated if p205 regulated the
expression of Rb, E2F1, p27KIP, p21WAF1/CIP1 and Cdks,
and if p205 was present in complexes with these proteins using
immunoprecipiation and glutathione-S-transferase (GST)-
pulldown assays. We found that while p205 inhibited cell
growth in a p53- and Rb-dependent manner, p205 can also in-
hibit growth in the absence of these regulatory factors. There-
fore, to discover what alternative growth regulatory pathways
may be controlled by p205, we used a yeast two-hybrid system
to identify unknown binding partners. Taken together, we
found that p205 can inhibit cell growth through Rb and/or
p53-dependent pathways, and detected p205 in protein com-
plexes that contain Rb and p53. In addition, p205 is capable
of recruiting alternate pathways of growth inhibition, and
may represent a novel therapeutic target that can be induced
or over-expressed to inhibit the growth in tumor cells with mu-
tated Rb and p53 proteins.2. Materials and methods
2.1. Cell lines
The human osteosarcoma cell lines U20s and Saos2 stably express-
ing the Tet repressor (kindly provided by Dr. Karen Vousden, Beatson
Institute for Cancer Research, Bearsden, Glasgow, UK) were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco-
BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum,
2 mM L-glutamine and 100 lg/ml penicillin and 100 lg/ml streptomy-
cin (P/S) (Gibco-BRL). The pTre-204 and pTre-205 plasmids, as well
as an empty vector control, were transfected into the U20s and Saos2
cell lines by CaPO4 precipitation, and selected for stable transfection
with 100 lg/ml hygromycin (Clontech, Mountain View, CA), and then
cloned by limiting dilution.
2.2. Cell viability and colony formation assays
U20s and Saos2 cell clones that conditionally express p204 and p205
were identiﬁed by Western blot analysis. Then, p205 and p204 induc-
ible cell lines were treated with 0.25 lg/ml doxycycline for 6 days be-
fore determination of cell numbers using trypan blue dye exclusion
and a hemocytometer. Cell viability in p205 and p204 expressing cell
lines was compared to control cell lines transfected with the empty
pTre vector in the presence or absence of doxycycline. For colony
formation assays, U20s and Saos2 cells were transfected with 5 lg
pCB6-204, pCB6-205 or pCB6 control expression plasmids using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA), and then 5 · 103 cells were
plated in 100-mm tissue culture dishes in DMEM supplemented with10% FBS, and P/S. The cells were allowed to grow for 10 days in
the presence of 50 lg/ml neomycin (Cellgro, Herndon, VA) with 2
medium changes after which they were washed, ﬁxed with methanol,
and stained with Giemsa (Sigma, St. Louis, MO). Colonies 2-mm or
greater in size were scored.
2.3. p204 and p205 expression plasmids
The primers 5 0-GCAGAATTCCGCACCATGGTGAATGAAT-
ACAAGAGAATT-3 0 and 5 0-GCAGGATCCTCACTTTCTAGC-
ATT-3 0 were used to amplify p204 cDNA (obtained from Peter
Lengyel, Department of Molecular Biophysics and Biochemistry,
Yale University, New Haven, CT), and the 1947-bp polymerase chain
reaction (PCR) product was digested with EcoRI and ligated into the
tetracycline-inducible eukaryotic expression vector pTre (Clontech),
which was linearized by digestion with EcoRI, and puriﬁed from a
0.8% agarose gel. Standard conditions for PCR were denaturation
at 94 C for 5 min, 30 cycles of 94 C for 30 s, 56 C for 30 s, and
72 C for 1 min, and a ﬁnal extension at 72 C for 7 min. Insert ori-
entation was screened by restriction enzyme digestion, followed by
dideoxynucleotide sequencing. The p205 coding sequence was simi-
larly ampliﬁed by PCR from p205 cDNA (obtained from Thomas
Hamilton (Research Institute, Cleveland Clinic Foundation, Cleve-
land, OH)) using the following primer pair: 5 0-GCAGAATTCCG-
CACCATGGTG- AATGAATACAAGAGAATT-3 0 and 5 0-
GCAGGATAATCACTGGACAGTTGA-3 0. Following ampliﬁca-
tion of the 1302-bp DNA fragment, the PCR product was digested
with EcoRI and subcloned into the pTre vector. For transient trans-
fection assays, p204 and p205 inserts were digested with BamHI/
EcoRI, and then cloned into the eukaryotic expression vector
pCB6+ (a gift from Dr. M. Ashcroft, CR-UK Centre for Cancer
Therapeutics, Institute of Cancer Research, Surrey, UK). A similar
cloning strategy was used to construct the pCB6-FLAG-204 and
pCB6-FLAG-205 vectors, which express p204/5 as fusion proteins
with a FLAG tag, and to insert p205 into the vector pGEX-4T-2
(Amersham Biosciences, Piscataway, NJ) which expresses p205 as a
fusion protein with a GST tag. The luciferase reporter vector
pWWP-LUC, was the kind gift of Dr. Bert Vogelstein, Howard
Hughes Medical Institute, Johns Hopkins Oncology Center, Balti-
more, MD. The Renilla luciferase vector phRL-null (Promega, Mad-
ison, WI) was obtained from Dr. Peter Johnson, National Cancer
Insitute-Frederick. For the yeast two-hybrid assay, p205 cDNA was
subcloned into the EcoRI sites of the yeast expression vector
pGBKT7 (Clontech), 3 0 to the Gal4 DNA-binding domain sequence.
Insert orientation was screened by restriction enzyme digests, fol-
lowed by dideoxynucleotide sequencing. Protein expression veriﬁed
by Western blot analysis of yeast cell extract following transforma-
tion of yeast strain AH109 with pGBKT7-205.2.4. Western blot analysis
Whole cell extracts were obtained by resuspending cell pellets in lysis
buﬀer (300 mMNaCl, 1.5 mMMgCl2, 25 mMHEPES (pH 7.5), 20 mM
b-glycerophosphate and 0.1% Triton X-100) with complete mini prote-
ase inhibitor cocktail (Roche, Manneheim, Germany) on ice for
30 min. Protein concentration was determined by BCA protein assay re-
agent (Pierce, Rockford, IL) using a Multiskan Spectrum spectropho-
tometer (Thermo Electron Corp., Franklin, MA). Thirty micrograms
ofwhole cell extractwasdenaturedbyboiling for 10 min in sodiumdode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) sample
loading buﬀer, separated on 4–12% gradient SDS–PAGE and trans-
ferred to Immobilon-P PVDF membrane (Millipore, Bedford, MA)
for immunoblotting. In order to verify that equal protein amounts were
transferred in each lane of the gel, themembraneswere stainedwith Pon-
ceau S (Sigma, St. Louis, MO). The immunoblots were developed using
HRP-conjugated secondary antibodies (Promega, Madison, WI) and
LumiGlo HRP substrate (New England Biolabs, Beverly, MA). Chemi-
luminescence was detected by exposing the immunoblots to RAR ﬁlm
(Eastman Kodak Co., Rochestor, NY) for times ranging from 5 s to
3 min. The anti-p205 antibody was generated in rabbits against a ﬁfteen
amino acid sequence corresponding to the C-terminus of p205 (NH2-
KVTKAGKKKEASTVQ-COOH) (Cocalico Biologicals, Inc., Reams-
town, PA). The anti-p204 antibody (which is also speciﬁc for p205) was
the generous gift of Dr. Santos Landolfo, Department of Public Health
and Microbiology, Medical School of Torino, Italy. Immunoblots were
stripped by incubation in 200 mMglycine (pH 2.5), 0.05% Tween-20 for
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Biotechnology, Inc., Santa Cruz, CA) was performed to verify equal
loading of the samples.
2.5. RT-PCR analysis
Total RNA was isolated using the RNeasy mini kit (Qiagen Inc.,
Valencia, CA) and reverse transcribed using the Superscript First-
strand Synthesis system from Gibco BRL, Gaithersburg, MD. PCR
ampliﬁcation was achieved using the PCR Supermix kit from Invitro-
gen, and the following p21-speciﬁc primers: forward: 5 0-CTGCCCAA-
GCTCTACCTTCC-3 0, reverse: 5 0-CCCGCAGTATCTTGCCTCC-3 0.
PCR conditions were as follows: 5 min denaturation followed by 30 cy-
cles of denaturation 1 min at 95 C, annealing at 55 C for 45 s, exten-
sion at 72 C for 1 min.
2.6. Yeast two-hybrid assay
The yeast bait expression vector pGBKT7-p205, consisting of the
GAL4 DNA-binding domain fused to the p205 gene, was co-trans-
formed into the yeast strain AH109 (Clontech) along with a prey vec-
tor pACT2 expressing a 17-day murine embryo cDNA library fused to
the GAL4 activating domain (Clontech). Two-hybrid screening was
performed according to speciﬁcations of the manufacturer, and pro-
tein–protein interaction was then detected by transactivation of two re-
porter constructs; the yeast HIS3 gene and the Escherichia coli lacZ
gene. All HIS3+, b-galactosidase-positive clones were then subjected
to a second round of screening without the bait construct to eliminate
auto-activating inserts, and then re-screened with the bait construct to
conﬁrm protein–protein interaction. After the second round of screen-
ing, clones were sequenced with vector-speciﬁc primers, and the se-
quences analyzed using BLAST. Positively identiﬁed clones were
then subjected to further analysis for in vitro protein–protein interac-
tion using GST pull downs and co-immunoprecipitations.
2.7. GST pull down and immunoprecipitation assays
GST fusions were expressed in the E. coli BL21 expression strain, and
aﬃnity puriﬁed using glutathione–Sepharose beads as instructed by the
manufacturer (AmershamBiosciences, Piscataway,NJ ). The amount of
fusion protein loaded on the beads was determined by SDS–PAGE.One
microgram of fusion protein was pre-loaded onto glutathione–Sephar-
ose beads. The beads were then incubated in blocking buﬀer consisting
of 0.25% gelatin, 50 mM KCl, 50 mM HEPES (pH 7.5) for 30 min at
room temperature, washed with binding buﬀer (150 mM NaCl, 50 mM
HEPES (pH 7.5), 0.1% Nonidet P-40), and incubated with cell extracts
from U20s at 4 C for 90 min. The beads were then washed ﬁve times
with bindingbuﬀer, afterwhich the boundproteinswere releasedbyboil-
ing in 1· SDS–PAGE sample loading buﬀer (Invitrogen, Carlsbad, CA)
and subjected to SDS–PAGE.
For immunoprecipitations, U20s and Baf3 cells were transfected
with pCB6-FLAG-205 vector by electroporation using a BTX Electro
Cell Manipulator 600 (Biotechnologies & Experimental Research, Inc.,
San Diego, CA) as previously described [11]. Cell lysates were prepared
24 h post-transfection and incubated at 4 C for 1 h with anti-FLAG
antibody followed by 1 h incubation with protein A–agarose beads
(Sigma–Aldrich, St. Louis, MO). The beads were washed ﬁve times
with protein extraction buﬀer, and the bound proteins released in
extraction buﬀer supplemented with 500 mM NaCl, and visualized
by Western blot analysis.
2.8. Cell cycle analysis
p204 and p205 expression was induced in U20s and Saos2 cell lines
by treatment with 0.25 lg/ml doxycycline over a period of 6 days. One
million cells were pelleted, washed twice with phosphate buﬀered saline
(PBS) with 0.01% bovine serum albumin (BSA), resuspended in 1 ml of
ice-cold 70% ethanol, and then incubated on ice for 30 min. Following
ﬁxation, the cells were resuspended in 500 ll PBS containing 0.01%
BSA, 1 mg/ml RNase A and 40 lg/ml propidium iodide (Sigma) and
incubated at 37 C for 20 min, then analyzed by ﬂow cytometry.
2.9. Luciferase assays
Saos2 cells (1 · 105) were plated in triplicate in 500 ll growth
medium without antibiotics, and 24 h later, were transfected with
DNA diluted in Opti-MEM reduced serum medium (Invitrogen).
After another 24 h, cells were lysed with 100 ll passive lysis buﬀer(Promega). Twenty-ﬁve microliters of cell lysates were analyzed for
luciferase activity on a microplate luminometer (CR&R Berthold
biological instruments, Bad Wildbad, Germany), using the Dual
Luciferase Assay system (Promega). All luciferase activity readings
were normalized relative to the activity of the Renilla luciferase
control, as per the manufacturer’s instructions.
2.10. Cdk kinase assays
Baculovirus-produced Cdk2 (0.08 lg) was activated by phosphoryla-
tion on Thr160 by 12.8 ng GST-Cak1p for 90 min in the presence of
3 mM ATP. GST-cyclin A (0.385 lg) [truncated form comprising ami-
no acids 174–432] and diluted GST-p205 [0; 1; 0.5; 0.25; 0.083, 0.027
and 0.0093 lg] was added followed by 5 lCi [c-32P] ATP. After incuba-
tion for 30 min at room temperature, the reaction was terminated by
the addition of 4 ll 5· SDS-sample buﬀer. Samples were heated to
95 C, run on 12.5% SDS–polyacrylamide gels [Criterion, Bio-Rad],
and analyzed by phosphorimaging [Storm820, Molecular Devices].3. Results
3.1. p205 inhibits cell proliferation via Rb/p53-dependent
and -independent pathways
To deﬁne the mechanism of p205-mediated growth inhibi-
tion, we over-expressed p205 by transient transfection or using
a conditional expression system in osteosarcoma cell lines,
which express functional Rb and p53 proteins (U20s) or are
defective for Rb and p53 expression (Saos2). We compared
the closely related family member p204, which was previously
determined to induce growth arrest via an Rb-dependent
mechanism [14,15]. U20s and Saos2 cell lines were transiently
transfected with pCB6-p204 and pCB6-p205 expression plas-
mids, and then plated in colony formation assays. p205 and
p204 protein expression was veriﬁed by Western blot analysis
after 24 and 48 h, and equal loading was determined by actin
expression (data not shown) (Fig. 1A). Over-expression of
p204 and p205 in U20s (Rb+/+, p53+/+) inhibited colony for-
mation by 89 ± 11% and 78 ± 8%, respectively (Fig. 1B). Sur-
prisingly, both p204 and p205 were also eﬀective in inducing
growth arrest in Saos2 (Rb/, p53/), indicating that
p204 and p205 can induce growth arrest in the absence of
p53 and/or Rb.
We conﬁrmed these observations in stably transfected U20s
and Saos2 cell lines that conditionally express p204 and p205
in the presence of the tetracycline analog, doxycycline. In this
regard, p205 and p204 are induced by doxycycline in U20s and
Saos2 cells in a time-dependent manner (Fig. 2A and B, and
Fig. 3A and B). The levels of p205 expression in doxcycline-
treated U20s and Saos2 cells were similar to those in myeloid
cell lines and normal bone marrow (data not shown). Induc-
tion of p205 expression in U20s cells treated with 0.25 lg/ml
doxycycline for 6 days resulted in 32 ± 3% growth inhibition
as measured by viable cell count, compared to 23 ± 10%
growth inhibition upon expression of p204 (Fig. 2A). In com-
parison, induction of the Cdk inhibitor p21WAF1/CIP1 in U20s
resulted in 46% growth inhibition. In the Saos2 cells, induction
of p205 expression inhibits cell growth by 32%, compared to
induction of p204, which inhibits cell growth by 43%
(Fig. 2B). Induction of p21 expression inhibits Saos2 cell
growth by 71 ± 1%. Thus, over-expression of p204 and p205
can inhibit osteosarcoma cell line proliferation in a p53- and
Rb-independent manner. However, these experiments do not
exclude the possibility that p205 can also inhibit cell growth
through Rb- and p53-dependent pathways.
Fig. 1. Transient expression of p205 results in growth inhibition in
both U20s (Rb+/+/p53+/+) and Saos2 (Rb//p53/) cell lines. U20s
and Saos2 cells were transfected with the indicated plasmid according
to procedures described in Section 2. Protein expression was veriﬁed by
Western blot analysis with p204-, p205- and actin- (data not shown)
speciﬁc antibodies (panel A). Colonies greater than 2 mm in size were
enumerated after 10 days in culture (panel B). The data represents the
mean ± S.D. of four independent experiments.
Fig. 2. p204 and p205 inhibit the growth of U20s and Saos2
oesteosarcoma cell lines. Panels A and B. U20s and Saos2 cell lines,
respectively, were seeded in triplicate at 5 · 103 cells/ml and cultured
for 6-days in the presence or absence 0.25 lg/ml doxycycline, and then
viable cell numbers were determined by trypan blue dye exclusion
assay. The data above represents the average of four experiments.
Induction of p205 and p204 expression (inset panels A and B) was
determined by Western blot analysis as described in Section 2.
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levels
Based on the observation that p205 over-expression could
promote cell cycle arrest, we sought to identify what other
cell cycle regulators could mediate p205’s inhibitory eﬀects.
In this regard, p202 has previously been reported to induce
p21CIP/WAF protein expression [16], therefore we determined
the eﬀect of p205 on cell cycle regulatory proteins including
p21CIP/WAF and p27KIP. p205 upregulates the expression of
the Cdk inhibitor p21CIP/WAF in U20s cells in a time-dependent
manner, while p204 has no eﬀect on p21CIP/WAF expression
(Fig. 3A). In addition, p205 and p204 up regulates p27KIP to
a much lesser extent. Thus, induction of p21CIP/WAF in U20s
cells is speciﬁc to p205.
In comparison, p205 does not induce p21CIP/WAF expression
in Saos2 cells suggesting that p205 induces p21CIP/WAF in a
p53-dependent manner (Fig. 3B). Furthermore, p205 does
not induce p27 protein in Saos2 cells. Finally, p204 readily in-
duces p21CIP/WAF expression in the Saos2 cells, while it does
not induce p21CIP/WAF protein in U20s cells, suggesting that
p204 induces p21CIP/WAF in a p53-independent manner. There-
fore, p204 and p205 have divergent mechanisms of growth
inhibition involving p53-dependent induction of p21CIP/WAF
expression.
To evaluate if p205 induces p21 expression by modulating
the transcriptional activity of p53 on the p21 promoter, we
co-transfected a p205 expression vector (pCB6-205) and a
p21 promoter-luciferase reporter plasmid (pWWP-luc) with
or without pCB6-p53, into the p53-deﬁcient Saos2 cell line.Increasing amounts of the p205 expression plasmid had no ef-
fect on p21 promoter activity as measured by the luciferase re-
porter gene activity. However, enforced expression of p53
increased p21 reporter activity, and the addition of a p205
expression plasmid enhanced p21 promoter activity in a
dose-dependent manner in the presence of p53 (Fig. 3C). To
verify these results, we evaluated p21 protein and mRNA
expression levels by Western blot and RT-PCR analysis,
respectively, in cells following p205 induction. As shown in
Fig. 3D, p205 up regulated p21 mRNA and protein expression
in U20s, but not Saos2 cells, while p204 induces p21 mRNA
and protein expression only in Saos2 cells. Therefore, p205
may synergize with p53 to up regulate p21 expression in
U20s cells, and thus promote growth inhibition. The steady-
state levels of p53 protein, which are known to induce expres-
sion of p21 [17], were unaltered by p205 induction (data not
shown). Thus, our results demonstrate a functional interaction
between p205 and p53 in the induction of p21. To identify the
possible mechanisms involved, we determined if p205 physi-
cally interacts with p53. In pull down assays, we found that
GST-p205, but not GST alone, can bind speciﬁcally to p53
(Fig. 4A). This observation was conﬁrmed by co-immunopre-
cipitation of p205 and p53 in U20s cells. Speciﬁcally, p53 was
detected in immunoprecipitates of cell lysates obtained from
U20s cells transfected with pCB6-FLAG-p205 using antibod-
ies that recognize FLAG-tagged p205 by Western blot analysis
(Fig. 4B). p205 can therefore directly associate with p53, and
may modulate its transcriptional activity. In this manner,
Fig. 3. Induction of p205 expression increases the p21 and p27 protein levels in U20s cells. Panel A. U20s cells were cultured in the presence or
absence of 0.25 lg/ml doxycycline for 24, 48 and 72 h. Whole cell lysates were prepared, and equal amounts of protein (30 lg) were analyzed for p21
and p27 protein expression by Western blot analysis. Panel B. Induction of p204 but not p205 expression induces p21 protein levels in Saos2 cells.
Cell lysates were obtained from Saos2-p205, Saos-p204 and Saos2-control cells cultured in the presence or absence of 0.25 lg/ml doxycycline for 72 h.
Thirty micrograms of cell extract was analyzed for the expression of p21, p27, PCNA, and a-actin control to verify equal loading by Western blot
analysis. Panel C. p53-dependent transactivation of p21 promoter by p205. Saos2 cells were transfected with a reporter plasmid pWWP-LUC, which
contains the p21 promoter linked to the luciferase gene with increasing amounts of pCB6-205 plasmid in the presence or absence of 200 ng pCB6-p53
plasmid. Luciferase activity was measured 24 h later and plotted in relative light units (RLU) as compared to internal control Renilla luciferase
activity. Panel D. p21 mRNA induction in U20s and Saos2 cells. Total RNA was insolated from U20s and Saos2 cells following expression of p205,
which was reverse transcribed and ampliﬁed using p21-speciﬁc primers according to the procedures described in Section 2. As a control, RNA
preparations were also ampliﬁed with b-actin primers. Protein lysates were simultaneously harvested, and for each timepoint, 30 lg of protein was
run on an SDS–PAGE gel, then analyzed by Western blot analysis for p21 protein expression. Blots were then stripped and re-probed for a-actin
protein.
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3.3. p205 regulates Rb expression, and binds Rb in vitro and
in vivo
Based on the observation that p205 can function in both a
p53-dependent and p53-independent manner, we evaluated if
p205 might also promote cell growth through Rb-dependent
and Rb-independent pathways. In this regard, p205 contains
a potential Rb-binding motif (LXCXE), which is present in
all IFI-200 family members. This domain accounted for the
ability of p202 [18] and p204 [14] to bind Rb, and deletion
of this motif in p204, or the absence of Rb, results in the abro-
gation of p204 antiproliferative activity [19]. To determine if
p205 also inhibits cell growth in an Rb-dependent manner,
we ﬁrst examined Rb expression after induction of p205expression in U20s cells. We found that enforced expression
of p205 and p204 signiﬁcantly increased the levels of Rb
expression in U20s cells, and observed an increase in the hyp-
ophosphorylated form of Rb (Rbhypo) (Fig. 5A and B). Rbhypo
acts as a transcriptional repressor by binding the E2F/DP1
protein complex and preventing E2F-initiated transcription
of genes that stimulate cell proliferation [20–22]. Upregulation
of Rb expression in U20s cells by p205 and p204 correlates
with decreased expression of proliferating cell nuclear antigen
(PCNA) expression and c-myc, which are markers for de-
creased cell proliferation (Fig. 5A). E2F1 levels were also par-
tially decreased by p205, but not p204, expression. However,
induction of p205 or p204 did not signiﬁcantly alter the protein
levels of Cdk2 in U20s. In addition, expression of the INK4
family of Cdk inhibitors (p16INK4a, p18 and p19ARF) was
not aﬀected by p204 and p205 expression (data not shown).
Fig. 4. p205 associates with p53. Panel A. Whole cell U20s extracts
were incubated with pre-blocked glutathione–Sepharose beads loaded
with equal amounts of GST or GST-p205. After washing, the beads
were boiled in loading buﬀer and run on a SDS–PAGE gel. After
transfer onto a PVDF membrane, immunoblotting was performed
with a p53-speciﬁc antibody (clone Pab-246 from Santa Cruz Biotech).
Panel B. U20s cells were transfected with pCB6-FLAG-p205, and cell
lysates prepared after 24 h. Lysates were treated with FLAG-speciﬁc
antibody (M1 mouse monoclonal antibody from Sigma, St. Louis,
MO), or mouse isotype control, then immunoprecipitated with protein
A–sepharose. Western blot analysis was then performed using a p53-
speciﬁc antibody.
Fig. 5. p204 and p205 induce Rb expression, and repress the
expression of proliferation-speciﬁc markers. Panel A. U20s cell lines
were grown either in the absence, or presence of 0.25 lg/ml doxycycline
over a 24-, 48- and 72-h period. Whole cell extracts were prepared and
equal amounts of protein (30 lg) were analyzed by Western blot
analysis, and probed with antibodies that detect Rb and hypophosph-
orylated Rb (the transcriptionally repressive form of Rb), E2F1,
PCNA, c-Myc, Cdk2, and a-actin (loading control). The Rb antibody
(clone G3-245), PCNA (PC10), c-Myc (C-33) and Cdk2 (M2) and a-
actin (C-2) antibodies were obtained from Santa Cruz Biotechnology,
Santa Cruz, CA, while the Rbhypo antibody was obtained from
Biosource, Camarillo, CA. Panel B. Densitometric analysis of Rb
protein expression following induction of p204 and p205. Densito-
metric analysis was performed by scanning Western blots using Epi
Chemi II Darkroom scanner from RM Taylor Enterprises, Columbia,
MD. Relative band intensity is represented by relative densitometric
units (RDU).
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expression of Rb and Rbhypo in U20s cells.
We have previously shown that truncation of the p205 pro-
tein that contains the Rb-binding domain signiﬁcantly dimin-
ishes its anti-proliferative activity [11]. Therefore, we next
evaluated whether p205 associates directly with Rb in vitro
using GST-pull down assays, or in cells via co-immunopre-
cipitation of an Rb-p205 protein complex. Whole cell ex-
tracts were prepared from U20s and incubated with GST
or GST-p205 immobilized and pre-blocked on glutathione–
Sepharose beads. Proteins bound to p205 were resolved by
SDS–PAGE and analyzed by Western blotting with an Rb-
speciﬁc antibody. Our results indicated that Rb is pulled
down by GST-p205, but not GST alone, suggesting that
p205 can bind to Rb (Fig. 6A). In a similar fashion, we were
able to detect interaction of p205 with p130, an Rb isoform.
In a reciprocal experiment, we found that p205 speciﬁcally
interacts with the central region of Rb, including a pocket re-
gion bearing the LXCXE docking peptide, as determined by
GST pulldown of p205 using a truncated form of Rb retain-
ing the Rb pocket region. Therefore, p205 appears to interact
with Rb in the same manner as other LXCXE motif pro-
teins, including p202 [18] and p204 [14]. The GST pull downs
were veriﬁed by immunoprecipitating p205 with a FLAG tag,
then probing for Rb via Western blot analysis (Fig. 6B). We
identiﬁed two distinct bands, which may represent the phos-
phorylated and non-phosphorylated forms of Rb (Fig. 6B).
In contrast to p202, which binds only to the hypophosphory-
lated form of Rb [18], p205 appears to interact with both
forms of Rb.3.4. Cell cycle analysis following induction of p205
Since p205 induces growth arrest in cells that express Rb and
p53 (U20s), as well as Rb and p53 deﬁcient (Saos2) cell lines,
we investigated if induction of p205 induced cell cycle arrest
or apoptosis. p204 and p205 expression were induced in
U20s and Saos2 cell lines by treatment with doxycycline over
6 days, and cells were harvested for cell cycle analysis by pro-
pidium iodide staining. Measurement of the DNA content
these cells indicated little, of any, induction of apoptosis by
p204 or p205 expression (data not shown). Moreover, induc-
tion of p204 and p205 expression in U20s cell lines had a neg-
ligible eﬀect on cell cycle progression (Table 1). In contrast,
p204 and p205 induced a partial G2/M arrest in Saos2 cells,
as they induced a 62% and 61% increase in G2/M phase accu-
mulation, respectively. Thus, while induction of p205 and p204
may prolong all phases of the cell cycle in U20s cells, it pro-
motes the accumulation of cells in the G2/M phase in cells that
lack the expression of Rb and p53 (Saos2). Similar results were
Fig. 6. p205 interacts with Rb and p130. Panel A. Whole cell extracts
from U20s cells were incubated with GST and GST-p205, and
analyzed by Western blot analysis. Immunoblotting was performed
using anti-Rb and p130 (C20, Santa Cruz Biotech) antibodies.
Similarly prepared extracts were also incubated with GST-Rbdp, a
GST fusion of the LXCXE-binding pocket region of Rb, and then
analyzed by Western blot analysis using an antibody speciﬁc for p205.
Panel B. Baf3 cells were transfected with pCB6-FLAG-p205, and cell
lysates were prepared after 24 h. Lysates were treated with FLAG-
speciﬁc antibody, or mouse isotype control, then immunoprecipitated
with protein A–sepharose. Western blot analysis was then performed
using an Rb-speciﬁc antibody.
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after a 3-day period (data not shown).
3.5. p205 binds to Cdk1 and Cdk2, and is phosphorylated by
Cdk2
To investigate if p205 contributes to G2/M arrest by regulat-
ing Cdk1 and/or Cdk2 activity, which is important for both
G1/S [23] and G2/M progression [24], we ﬁrst assayed if aﬃn-
ity-puriﬁed GST-p205 binds to Cdk1 or Cdk2. As shown in
Fig. 7A, GST-p205 pulls down both Cdk1 and Cdk2 present
in U20s cell lysate. Furthermore, this interaction was speciﬁc
to these proteins, as GST-p205 does not pull down Cdk4
and Cdk6 (data not shown). We also assayed the ability of
p205 to modulate Cdk1 and Cdk2 phosphorylation activity.
We determined that GST-p205 does not aﬀect the activationTable 1
Expression of p204 and p205 results in G2/M block in Saos2, but not U20s
Strain G0/G1 phase (%) S-
Doxycycline D
 + 
U20s-control 50.2 44.3 38
U20s-204 57.4 55 32
U20s-205 47.4 49.7 39
Saos2-control 54.6 57.1 29
Saos2-204 61.8 47.5 26
Saos2-205 54.9 47 29
p204 and p205 expression was induced by 0.25 lg/ll doxyxycline treatment
minimum 20000 cells per sample were analyzed by FACS. Three independent
the results above indicate, both p204 and p205 induce G2/M cell cycle arresof the Cdk proteins by Cdk activating kinase (CAK) [25,26],
nor does it signiﬁcantly impede their ability to phosphorylate
histone H1 substrate (data not shown). However, our results
are consistent with GST-p205 itself being a substrate for
Cdk2 phosphorylation, while there is negligible phosphoryla-
tion on GST alone (Fig. 7B). On the other hand, GST-p205
is not the substrate for Cdk1 phosphorylation activity (data
not shown). Aﬃnity-puriﬁed GST-p205 was detected as a sin-
gle protein species, which migrated with an apparent molecular
weight of 80 kDa in these gels (data not shown). Thus, while
the consequences of p205 phosphorylation by Cdk2 remain
to be investigated, Cdk2 may regulate p205 activity in vivo
to promote cell cycle progression.
3.6. Identiﬁcation of a p205–HoxB2 interaction via the yeast
two-hybrid assay
Collectively, our data indicate that p205 may induce growth
inhibition via pathways other than Rb and p53, therefore we
attempted to identify these alternative pathways using a yeast
two-hybrid screen. p205 was expressed as a fusion protein with
the GAL4 DNA-binding domain in the S. cerevisiae strain
AH109, and used as bait to screen a mouse 17-day embryo
MATCHMAKER cDNA library. The two-hybrid screen
yielded 10 positive clones with matching entries in the Entrez
Nucleotide database. One encoded the 53BP3 protein, whose
function beyond p53 binding is unknown. Interestingly, a
p53-binding protein (53BP) homolog, 53BP1, was also isolated
in a similar yeast two-hybrid screen using another family mem-
ber, p202, as bait [27]. This indicates that p202 and p205 both
possess an ability to bind the 53BP, and in addition, may share
a conserved mechanism for modulating p53 transcriptional
activity via this interaction. Analyzing the other sequences,
we found that six of them encoded transcriptional regulators.
One transcription factor identiﬁed, Miz1, is a zinc-ﬁnger pro-
tein that interacts with c-Myc to repress the p21 promoter
[28–30]. Other transcription factors included 4 paired homeo-
domain proteins; Pax6, a zinc-ﬁnger transcription factor that
has been implicated in embryonic ocular development
[31,32], Prx2, which is critical for craniofacial and limb mor-
phogenesis in murine embryos [33,34], GATA6, a member of
the GATA family of zinc ﬁnger proteins which regulates the
diﬀerentiation of distal lung epithelium [35], and the murine
homolog of HoxB2, which is implicated in the early stages of
erythroid, megakaryocytic and myeloid diﬀerentiation [36].
We focused on characterizing the interaction of p205 withcell lines
phase (%) G2/M phase (%)
oxycycline Doxycycline
+  +
.9 43.2 10.9 12.5
.6 33.6 10 11.4
41.5 13.6 8.8
.2 27.5 16.2 15.4
32.6 12.3 19.9
.5 28.1 15.5 24.9
over 6 days. Cells were harvested and stained with propidium iodide,
assays were performed; a representative experiment is shown above. As
t in Saos2, but not U20s cells.
Fig. 7. p205 associates with Cdk1 and Cdk2, and is phosphorylated by
Cdk2. Panel A. Binding of p205 to Cdk1 and Cdk2 in vitro. Direct
binding of p205 to Cdk1 and Cdk2 was assayed by incubating U20s
cell lysates with GST-205 immobilized on glutathione–Sepharose
beads for 90 min at 4 C. After puriﬁcation, bound proteins were
released by boiling and analyzed by Western blot analysis using anti-
Cdk1 and Cdk2 antibodies (Pharmingen). Panel B. Cdk2 Kinase assay.
Cdk2 (0.08 lg) was activated by phosphorylation with 12.8 ng GST-
Cak1p. GST-cyclin A (0.385 lg) was added as well as the following
dilutions of GST-p205: Cdk2 control, 0 lg; 1, 1 lg; 2, 0.5 lg; 3, 0.25 lg;
4, 0.083 lg; 5, 0.027 lg; 6, 0.0093 lg; and incubated with 5 lCi [c-32P]
ATP. As a control, activated Cdk2 and cyclin A were also incubated
with the same dilutions of GST protein.
Fig. 8. p205 interacts with the murine homolog of HoxB2. Panel A.
Binding of Hox B2 to GST-p205. GST-p205 on glutatione–Sepharose
beads were incubated with 100 lg total cell lysate prepared from
mouse BMC, and bound proteins were released and analyzed by
Western blotting using an antibody speciﬁc for Hox B2 (P-20) from
Santa Cruz Biotech. Panel B. Immunoprecipitation of p205 with anti-
Hox B2 antibody. MPRO cell lysate was prepared and incubated with
either control mouse isotype antibody, or anti-Hox B2 antibody.
Immunoglobins were then precipitated with protein A–sepharose and a
Western blot analysis performed using p205-speciﬁc antibody.
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inﬂuence hematopoietic stem cell proliferation and diﬀerentia-
tion. We found that GST-p205 could pull down HoxB2
(Fig. 8A). We also immunoprecipitated p205 using anti-HoxB2
antibody, further conﬁrming their interaction (Fig. 8B). Thus,
addition to corroborating a previously identiﬁed target for
p205; the 53BP protein [27], we also identiﬁed unique targets
including Miz-1, and Hox B2, which directly binds to p205.4. Discussion
In this study, we report that p205 inhibits cell growth in the
presence and absence of p53 and Rb. Speciﬁcally, we found
that p205 and p204 induce cell growth inhibition of Saos2
(p53/, Rb/) cells, demonstrating that p205 can regulate
cell proliferation independent of either transcription factor.
However, we also discovered that p205 interacts with both
Rb and p53, and that these interactions aﬀect aspects of
p205 activity. In this regard, we found that p205 requires the
presence of p53 to up regulate the cell cycle inhibitor p21,
and that induction of p21 protein results in growth inhibition
(Fig. 2A and B). Given that p205 and p53 apparently synergize
to induce p21, it is possible that p205 promotes the ability of
p53 to transactivate the p21 promoter, possibly by enhancing
its ability to bind the p21 promoter. The human homolog
IFI-16 has been reported to interact with p53 in a similar man-
ner to augment the p53-dependent transactivation of p21
expression [37].
We also implicate Rb in p205-mediated growth inhibition,
since p205 upregulates Rb protein levels in wild-type cells. In
addition, we found an even more striking correlation between
p204 expression and upregulation of Rb protein. Consistent
with our ﬁndings, Gutterman et al. have previously demon-
strated that over-expression of p202 results in substantial in-creases in total Rb levels, including hypo-phosphorylated
Rb, in AKR-2B cells suggesting that a number of p200 family
member upregulate Rb[16]. To date, very little is known con-
cerning the regulation of Rb expression in normal cells, but
it is possible that p202, p204 and p205 may regulate Rb protein
levels either through enhancing protein stability, or through
transcriptional regulation. In addition, p205 initiates repres-
sion of downstream Rb target genes c-Myc and PCNA.
E2F1, whose transcriptional activity is directly regulated by
Rb, is also down regulated by p205. p205 may regulate Rb
transcriptional activity by binding to it, as shown by GST pull
downs and immunoprecipitations, and preventing its inactiva-
tion through phosphorylation by Cdks. In this regard, we have
previously demonstrated that mutating the Rb-binding sites of
p205 signiﬁcantly attenuates its ability to induce growth inhi-
bition [11]. Thus, p205 appears to aﬀect both Rb- and p53-
mediated pathways of cell cycle regulation to repress cell
growth. In addition to these complex functional interactions,
it is also possible that p205 dimerizes with itself, or with other
members of the IFI-200 family of proteins, to mediate their
physiological functions.
p204 has been reported to inhibit cell growth in an Rb-
dependent manner, as it is unable to induce growth arrest in
Rb/ murine embryo ﬁbroblasts, or Rb-deﬁcient cell lines
Saos2 and C33A, and its anti-proliferative eﬀect was abolished
by deleting its Rb-binding domains [14]. However, in contrast
to these ﬁndings, we observed that p204, like p205, is able to
inhibit growth in a p53 and Rb-independent manner. While
we are unable to provide explanation for this diﬀerence, an-
other family member, p202, also induces cell cycle retardation
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expression of p21 in Saos2 and promotes growth arrest [16].
Thus, the ability to inhibit cell growth in the absence of p53
and Rb is a property shared amongst other IFI-200 family
members. Furthermore, this novel function of p200 family
members could potentially be exploited to inhibit the growth
of cancer cells that have mutated Rb and p53 pathways.
Interestingly, p204 and p205 inhibit growth in U20s cells
without arresting the cells in a particular phase of the cell cy-
cle, an observation that is similar to results obtained from a
previous study on p202 [16]. Furthermore, the observation
that p204 induces p21 expression in Saos2 cells, while p205
has no eﬀect, while both induce G2/M arrest in the same cell
line, suggest that these two p200 family members use an alter-
nate mechanism(s) of growth inhibition. It is possible that
that G2/M arrest by p205 may involve interaction with
Cdk1 and Cdk2, as suggested by GST pull downs, although
p205 does not directly aﬀect Cdk activity on histone H1 [38].
In this regard, p202 has been shown to directly inhibit the
kinase activity of Cdk2 [16]. Further, p205 itself may be a
substrate for regulation by Cdk2, which phosphorylates
p205 in vitro. This may be a means by which Cdk2 regulates
p205 activity in vivo, and may explain how myeloid lineage
cell lines such as myeloid progenitor cell line (MPRO) and
WEHI maintain high proliferation rates, while tolerating high
levels of p205 expression [10]. It is noteworthy that Western
blot analysis of p205 in MRPO lysates consistently yields a
slower-migrating band in addition to that of p205 (47 kDa),
which may correspond to the phosphorylated, putatively
inactive, form of p205. Finally, experimental evidence sug-
gests that p205-mediated growth inhibition does not involve
induction of apoptosis [11].
Since we found that p200 family members act through no-
vel pathways of growth inhibition that are independent of Rb
and p53, we sought to obtain information about these path-
ways via a yeast two-hybrid screen. As a result of this screen,
we identiﬁed six transcription factors that might interact with
p205, four of which are members of the paired homeodomain
family of proteins. Paired homeobox proteins are character-
ized by a conserved DNA-binding motif; the paired domain,
and have been implicated in early embryogenesis [39,40]. One
interesting candidate, the homeobox protein HoxB2, has been
shown to be critical for induction of myelomonocytic diﬀer-
entiation [36]. We validated that p205 and HoxB2 interact
using both GST pull downs and immunoprecipitations.
Experiments are in progress to determine if p205 attenuates
the ability of HoxB2 to promote hematopoietic stem cell
survival and proliferation. Thus, this screen provides novel
insights into the potential mechanism(s) by which p205
and other family members may regulate cell growth and
diﬀerentiation.
In summary, we have initially characterized the molecular
mechanism(s) by which p205 induces growth inhibition, which
include Rb- and p53-dependent and -independent pathways.
In this regard, p205 can be found in complexes with Rb and
p53 and can enhance the transcription activity of p53, and af-
fect the expression of target genes regulated by Rb. Further,
p205 can inhibit cell growth in cells that lack Rb and p53,
and thus may represent a novel mechanism to inhibit the
growth of cancer cells, which often have mutations in Rb
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